Refine by
Locations
- Europe
- Albania
- Andorra
- Austria
- Belarus
- Belgium
- Bosnia & Herzegovina
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Faroe Islands
- Finland
- France
- Germany
- Greece
- Hungary
- Iceland
- Ireland
- Italy
- Kosovo
- Latvia
- Liechtenstein
- Lithuania
- Luxembourg
- Macedonia
- Malta
- Moldova
- Monaco
- Montenegro
- Netherlands
- Northern Ireland
- Norway
- Poland
- Portugal
- Romania
- San Marino
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Turkey
- Ukraine
- United Kingdom
- Vatican City
Cancer Related Mutations Equipment Supplied In Europe
10 equipment items found
Manufactured by:TIB Molbiol Syntheselabor GmbH based inBerlin, GERMANY
In 2005 we developed our first LightMix Kit detecting bird flu Influenza A H5N1. Since then, we have created many kits testing for different pathogens, hematology markers, genetic mutations and polymorphisms. ...
Manufactured by:ViennaLab Diagnostics GmbH based inVienna, AUSTRIA
BRAF encodes a serine/threonine protein kinase, which plays an important role in signaling pathways involved in cell proliferation and differentiation. Determination of BRAF V600 mutational status is recommended in metastatic colorectal cancer (mCRC) at the same time as RAS mutational status for prognostic assessment (and/or potential selection for clinical trials). Testing of patients with ...
Manufactured by:Singleron Biotechnologies GmbH based inKöln, GERMANY
FocuSCOPE is a high-throughput single cell multi-omics sequencing solution that can detect both genetic variants and transcriptome from the same single cells. Thus, FocuSCOPE® provided a tool to decipher the connection between genotype and phenotype at single cell ...
Manufactured by:Sysmex Partec GmbH based inGoerlitz, GERMANY
Highly sensitive down to 0.06 % MAF, Able to detect 6 MM with 95 % confidence across all mutations (absolute quantification), High flexibility of between 2-16 samples/run, Fast TAT (2 days), Convenient software. Plasma-SeqSensei (PSS) BC RUO Kit allows for the highly sensitive and specific detection of mutations in circulating tumour DNA (ctDNA) from the plasma of patients with breast cancer. The ...
Manufactured by:MorphoSys AG based inPlanegg, GERMANY
Tulmimetostat is a second-generation EZH2 inhibitor that has been designed to achieve comprehensive target coverage through extended on-target residence time. EZH2 acts as an epigenetic writer and normally places one or more methyl groups on a histone protein, leading to the suppression of gene expression. Some cancers depend on an abnormal pattern of gene expression and re-direct EZH2 to genes ...
Manufactured by:OncoDNA S.A. based inGosselies, BELGIUM
OncoFOLLOW: The first personalised liquid biopsy in the market. Monitor the progression and detect lack of response. OncoFOLLOW is a test based on the analysis of circulating tumor DNA in blood. It is used to monitor the progression of the tumor (burden of the disease) and to detect lack of response or resistance to treatment as soon as it appears. This assay is customised for each patient, as it ...
Manufactured by:Hemogenyx Pharmaceuticals plc based inLondon, UNITED KINGDOM
Hemogenyx Pharmaceuticals utilizes postnatal human hemogenic endothelial cells (Hu-PHEC cells), discovered by Hemogenyx Pharmaceuticals’ Co-Founder Dr Vladislav Sandler, to generate cancer-free hematopoietic stem cells (HSC) for use in transplants to treat blood cancers with superior results. A patent for Dr Sandler’s work was issued in the US in February ...
Manufactured by:ORYX GmbH & Co. KG based inBaldham, GERMANY
Several cancers arise from the lack of DNA mismatch repair (MMR) resulting in the accumulation of thousands of single deletions or insertions at coding microsatellites (MSI-H). These mutations lead to the inactivation of specific proteins and to the expression of frameshift peptides (FSPs). These FSPs are tumor-specific antigens, which are constantly expressed. Cancers with MSI-H mutations ...
by:CDR-Life based inSchlieren, SWITZERLAND
CDR-Life’s T cell engaging antibodies are potentially transformative in the field of cancer immunotherapies» Prof. Markus G. Manz, MD, Head of Medical Oncology and Hematology at University Hospital and University of Zurich, Switzerland. CDR-Life’s pipeline is based on it’s unique antibody fragment platform. It includes a series of highly cancer-targeted and drug-based ...
Manufactured by:OncoDNA S.A. based inGosselies, BELGIUM
Oncodeep® is a comprehensive biomarker test designed to guide treatment of advanced, metastatic solid tumors. When your patients are diagnosed with a rare cancer type or an aggressive cancer, when chemotherapy doesn't work or when cancer comes back, OncoDEEP® can provide you with clear clinical guidance. Starting from a small sample of tumor tissue, our biomarker test is able to pinpoint ...